Roche, Zealand Pharma and obesity

Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal
The companies agreed to share profits for the therapy equally in the U.S. and Europe, but Roche will have exclusive rights to commercialization in the rest of the world.
Roche strikes $5.3B obesity treatment deal with Zealand Pharma
Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to develop its obesity drug candidate.
Roche Further Boosts Obesity Pipeline With Zealand Pharma Deal Worth $5.3 Billion For Weight Loss Drugs
Roche partners with Zealand Pharma on obesity drug petrelintide, with a $5.3B deal including milestone payments and global commercialization rights.
Roche agrees biggest-ever obesity drug deal
Roche has signed the biggest-ever obesity drug deal with a $5.3bn licensing agreement for a next-generation treatment from Danish biotech Zealand Pharma.
Roche, Zealand Pharma ink pact to co-develop, co-commercialise petrelintide as foundational therapy for obesity
Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma. Under the terms of this agreement, the two companies will collaborate
Hims & Hers, Zealand, and Roche fall: Why weight loss drug stocks are down today
Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 market — which is projected to hit $105 billion by 2030, according to Morgan Stanley (MS) analysts.
Roche signs $5.3 billion deal with Danish obesity drugmaker, Novo stock slides 4%
Roche is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker Zealand Pharma , the companies announced Wednesday. The deal would
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion
Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.
Roche-Zealand deal is the latest to boost obesity space
Viking Therapeutics (VKTX) stock gains as Roche (RHHBY) and Zealand Pharma's (ZLDPF) $5.3B deal for obesity drugs lifts weight loss drug stocks. Read more here.
Fierce Biotech4d
Roche pads out obesity pipeline, paying Zealand $1.6B upfront to codevelop amylin asset
Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...
Fierce Pharma5d
Roche overhauls Spark gene therapy unit, recording $2.4B in full impairment
Roche has recently launched a “fundamental reorganization” of Spark Therapeutics, the gene therapy unit that the Swiss pharma ...
Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly
Key Takeaways Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly.The Swiss ...
Roche And Zealand Team Up To Develop Petrelintide
Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...
Nasdaq4d
Zealand Pharma, Roche To Co-develop, Co-commercialize Petrelintide And Combination Products
Zealand Pharma will pay Roche $350 million ... dose combination product or next-generation petrelintide combination products being pursued under the collaboration agreement.
Zealand Pharma to pay $350M to Roche in petrelintide collaboration, license pact
Zealand Pharma (ZLDPF) and Roche (RHHBY) entered a collaboration and license agreement to co-develop and co-commercialize petrelintide as a ...
More popular acne products recalled due to cancer-causing chemical
Now more products have been recalled due to the same reason. Health reported Wednesday how L’Oréal took their popular La ...